Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza
- PMID: 19563891
- DOI: 10.1016/j.vaccine.2009.06.034
Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza
Abstract
The first influenza pandemic of the 21st century, due to a new strain of A(H1N1) virus, was declared on 11 June 2009 by the Director-General of the World Health Organization. Fortunately, the international community, including influenza vaccine manufacturers, has been increasing its preparedness for such an event, triggered by the need to stem the spread of the highly pathogenic avian influenza A(H5N1) virus over recent years. Today, the development of a pandemic influenza vaccine in the fastest possible time is a global priority. However, two major issues need to be taken into consideration: how long will it take to produce sufficient pandemic vaccine doses to immunize the global population at risk, including poor populations that have no resources to purchase the vaccine; and how will pandemic vaccine production affect availability of trivalent vaccine for the forthcoming 2009-2010 influenza season. To address these questions, WHO carried out a survey in May 2009 among influenza vaccine manufacturers on their planned seasonal and pandemic production with a view to developing recommendations on the distribution and use of pandemic influenza vaccine.
Similar articles
-
[Influenza vaccine: globalization of public health stakes].Med Trop (Mars). 2009 Aug;69(4):322. Med Trop (Mars). 2009. PMID: 19725377 French.
-
Achieving clinical equality in an influenza pandemic: patent realities.Seton Hall Law Rev. 2009;39(4):1137-72. Seton Hall Law Rev. 2009. PMID: 20718133
-
Swine flu pandemic. Developing countries to get some H1N1 vaccine--but when?Science. 2009 Nov 6;326(5954):782. doi: 10.1126/science.326_782. Science. 2009. PMID: 19892952 No abstract available.
-
Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective.Vaccine. 2011 Feb 1;29(6):1135-8. doi: 10.1016/j.vaccine.2010.11.042. Epub 2010 Nov 27. Vaccine. 2011. PMID: 21115061 Review.
-
Development of influenza vaccine production capacity by the Government Pharmaceutical Organization of Thailand: addressing the threat of an influenza pandemic.Vaccine. 2011 Jul 1;29 Suppl 1:A29-33. doi: 10.1016/j.vaccine.2011.04.120. Vaccine. 2011. PMID: 21684425 Review.
Cited by
-
Negotiating equitable access to influenza vaccines: global health diplomacy and the controversies surrounding avian influenza H5N1 and pandemic influenza H1N1.PLoS Med. 2010 May 4;7(5):e1000247. doi: 10.1371/journal.pmed.1000247. PLoS Med. 2010. PMID: 20454566 Free PMC article.
-
The Economic Case for a Pandemic Fund.Ecohealth. 2018 Jun;15(2):244-258. doi: 10.1007/s10393-018-1338-1. Epub 2018 May 21. Ecohealth. 2018. PMID: 29786132 Free PMC article.
-
Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology.Clin Microbiol Rev. 2010 Jan;23(1):74-98. doi: 10.1128/CMR.00032-09. Clin Microbiol Rev. 2010. PMID: 20065326 Free PMC article. Review.
-
The novel influenza A (H1N1) virus pandemic: An update.Ann Thorac Med. 2009 Oct;4(4):163-72. doi: 10.4103/1817-1737.56008. Ann Thorac Med. 2009. PMID: 19881161 Free PMC article.
-
Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.BMJ. 2010 May 27;340:c2649. doi: 10.1136/bmj.c2649. BMJ. 2010. PMID: 20508026 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
